Table I.
Demographic data of 40 patients receiving endocrine therapy for stage IV breast cancer.
| Parameters (n=40) | Patient no. (%) |
|---|---|
| Age (years) | 64 (range, 44-88) |
| Menopause | |
| Post-/premenopausal | 34 (85.0)/6 (15.0) |
| Degree of progression (metastasis) | |
| Bone or soft tissue/visceral | 21 (52.5)/19 (47.5) |
| Estrogen receptor | |
| Strongly positive/weakly positive | 33 (82.5)/7 (17.5) |
| Progesterone receptor | |
| Strongly positive/weakly positive | 14 (35.0)/26 (65.0) |
| HER2 | |
| Negative/positive | 36 (90.0)/4 (10.0) |
| Ki67 | |
| ≤14/>14% | 33 (82.5)/7 (17.5) |
| Treatment | |
| Letrozole/anastrozole/tamoxifen ± LHRH agonist/exemestane | 22 (55.0)/11 (27.5)/6 (15.0)/1 (2.5) |
| Clinical response | |
| CR/PR/SD ≥24 weeks/SD <24 weeks/PD | 0 (0.0)/30 (75.0)/4 (10.0)/2 (5.0)/4 (10.0) |
| Clinical response | |
| ORR/CBR/DCR | 30 (75.0)/30 (85.0)/4 (90.0) |
HER2, human epidermal growth factor receptor 2; LHRH, luteinizing hormone-releasing hormone; pCR, pathological complete response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; CBR, clinical benefit response; DCR, disease control rate.